First‐line cetuximab + platinum‐based therapy for recurrent/metastatic head and neck squamous cell carcinoma: A real‐world observational study—ENCORE

First‐line cetuximab + platinum‐based therapy for recurrent/metastatic head and neck squamous cell carcinoma: A real‐world observational study—ENCORE

Abstract Background ENCORE, an observational, prospective, open‐label study, investigated real‐world treatment practices and outcomes with cetuximab plus platinum‐based therapy (PBT) in first‐line (1L) recurrent and/or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN). Aims This mu...

Full description

Bibliographic Details
Main Authors:	Christophe Le Tourneau, Massimo Ghiani, Maria Chiara Cau, Roberta Depenni, Graziana Ronzino, Pierluigi Bonomo, Vincenzo Montesarchio, Luigi Leo, Jeltje Schulten, Satu Salmio, Diethelm Messinger, Andrea Sbrana, Edith Borcoman, Maria Grazia Ghi
Format:	Article
Language:	English
Published:	Wiley 2023-05-01
Series:	Cancer Reports
Subjects:	cetuximab combination chemotherapy first‐line observational study squamous cell carcinoma of head and neck
Online Access:	https://doi.org/10.1002/cnr2.1804

Similar Items

A Prospective Real-World Multi-Center Study to Evaluate Progression-Free and Overall Survival of Radiotherapy with Cetuximab and Platinum-Based Chemotherapy with Cetuximab in Locally Recurrent Head and Neck Cancer
by: Markus Hecht, et al.
Published: (2021-07-01)

Observational, prospective, phase 4 study in patients with first‐line recurrent and/or metastatic squamous cell carcinoma of the head and neck treated with cetuximab and platinum‐based therapy: DIRECT
by: Joël Guigay, et al.
Published: (2022-02-01)

Activity of platinum and cetuximab in cutaneous squamous cell cancer not amenable to curative treatment
by: Donata Galbiati, et al.
Published: (2019-12-01)

The dogma of Cetuximab and Radiotherapy in head and neck cancer – A dawn to dusk journey
by: Sapna Krishnamurthy, et al.
Published: (2022-05-01)

Phase I Study of Ficlatuzumab and Cetuximab in Cetuximab-Resistant, Recurrent/Metastatic Head and Neck Cancer
by: Julie E. Bauman, et al.
Published: (2020-06-01)

Organizing pneumonia secondary to cetuximab in a patient with colorectal cancer
by: Abdulaziz AlGhulayqah, et al.
Published: (2019-09-01)

Lutetium 177-Labeled Cetuximab Evaluation for Radioimmunotherapeutic Applications
by: Kamal Yavari, et al.
Published: (2012-06-01)

Transgenic goats producing an improved version of cetuximab in milk
by: Götz Laible, et al.
Published: (2020-11-01)

Local ocular safety of the subconjunctival injection of cetuximab in rabbits
by: Hossein Aghaei, et al.
Published: (2023-04-01)

Cetuximab in first line treatment of metastatic colorectal cancer
by: Carlo Barone, et al.
Published: (2012-07-01)

Cetuximab-Induced Aseptic Meningitis in a Patient with Colorectal Cancer: A Case Report and Review of Literature
by: Jakob Jäger, et al.
Published: (2022-11-01)

An Inflammatory Signature to Predict the Clinical Benefit of First-Line Cetuximab Plus Platinum-Based Chemotherapy in Recurrent/Metastatic Head and Neck Cancer
by: Stefano Cavalieri, et al.
Published: (2022-10-01)

Cetuximab-Taxanes-Platinum-Fluorouracil/Capecitabine (C-TPF/C-TPX) – a Feasible Option for Recurrent HNSCC with Negative Prognostic Factors. Literature Review with a Case Presentation
by: Camil Ciprian MIRESTEAN, et al.
Published: (2023-03-01)

Efficacy of Liver Chemoembolization after Prior Cetuximab Monotherapy in Patients with Metastatic Colorectal Cancer
by: Marcin Szemitko, et al.
Published: (2023-01-01)

Exosomes promote cetuximab resistance via the PTEN/Akt pathway in colon cancer cells
by: S. Zhang, et al.
Published: (2017-11-01)

Biomarkers of cetuximab resistance in patients with head and neck squamous cell carcinoma
by: Olivia Leblanc, et al.
Published: (2020-02-01)

The analysis of the circRNAs in the progress of acquired resistance to Cetuximab
by: Liping Yin, et al.
Published: (2022-06-01)

Dermopathy associated with cetuximab and panitumumab: investigation of the usefulness of moisturizers in its management
by: Watanabe S, et al.
Published: (2017-09-01)

Tracheal cancer treated with a short course of external and endoluminal radio-chemotherapy combined with cetuximab – a case report
by: Michael I. Koukourakis, et al.
Published: (2010-01-01)

Nationwide pharmacovigilance data for cetuximab-induced anaphylaxis and predictive model validation using prospective specific IgE detection
by: Kyung Hee Park, et al.
Published: (2021-07-01)

Analysis of translesion polymerases in colorectal cancer cells following cetuximab treatment: A network perspective
by: Anubrata Das, et al.
Published: (2024-01-01)

Interleukin‐33 as an early predictor of cetuximab treatment efficacy in patients with colorectal cancer
by: Xujun Zhang, et al.
Published: (2021-12-01)

Pharmacogenetic profiling and cetuximab outcome in patients with advanced colorectal cancer
by: Dahan Laetitia, et al.
Published: (2011-11-01)

Biweekly cetuximab and first-line chemotherapy in chinese patients with k-ras wild-type colorectal cancers
by: Wing-Lok Chan, et al.
Published: (2014-01-01)

Phase II Trial of CDX-3379 and Cetuximab in Recurrent/Metastatic, HPV-Negative, Cetuximab-Resistant Head and Neck Cancer
by: Julie E. Bauman, et al.
Published: (2022-05-01)

Effects of Cetuximab Combined with Celecoxib on Apoptosis and KDR and AQP1  Expression in Lung Cancer
by: Honggang XIA, et al.
Published: (2013-12-01)

Successful rechallenge with cetuximab after progression with nivolumab for recurrent cervical lymph node metastasis from carcinoma of the tongue
by: Yasuyuki Asada, et al.
Published: (2021-07-01)

Treatment outcomes of cetuximab-containing regimen in locoregional recurrent and distant metastatic head and neck squamous cell carcinoma
by: Tien-Hua Chen, et al.
Published: (2022-12-01)

Cetuximab Rechallenge and Monotherapy in Patients with Squamous Cell Carcinoma of the Head and Neck
by: Greg Knutzen, et al.
Published: (2015-11-01)

Cetuximab produced from a goat mammary gland expression system is equally efficacious as innovator cetuximab in animal cancer models
by: Qian Wang, et al.
Published: (2020-12-01)

Resveratrol Sensitizes Colorectal Cancer Cells to Cetuximab by Connexin 43 Upregulation-Induced Akt Inhibition
by: Yijia Wang, et al.
Published: (2020-04-01)

Engineering an Enhanced EGFR Engager: Humanization of Cetuximab for Improved Developability
by: Dennis R. Goulet, et al.
Published: (2022-01-01)

Predictive role of UCA1-containing exosomes in cetuximab-resistant colorectal cancer
by: Ying-nan Yang, et al.
Published: (2018-10-01)

Clinical Observation of mXELIRI and mFOLFIRI Combined with Cetuximab in First-line Treatment of Metastatic Left-side Colon Cancer
by: CHENG Jianping, et al.
Published: (2020-07-01)

Interleukin-1 alpha increases anti-tumor efficacy of cetuximab in head and neck squamous cell carcinoma
by: Madelyn Espinosa-Cotton, et al.
Published: (2019-03-01)

Chemotherapeutic Effectiveness of Combining Cetuximab for Metastatic Colorectal Cancer Treatment: A System Review and Meta-Analysis
by: Rong Li, et al.
Published: (2020-05-01)

Perioperative Cetuximab with Cisplatin and 5-Fluorouracil in Esogastric Adenocarcinoma: A Phase II Study
by: Caroline Gronnier, et al.
Published: (2023-04-01)

PUM1 Is Overexpressed in Colon Cancer Cells With Acquired Resistance to Cetuximab
by: Qizhi Liu, et al.
Published: (2021-08-01)

Cetuximab for esophageal cancer: an updated meta-analysis of randomized controlled trials
by: Ze-Hao Huang, et al.
Published: (2018-11-01)

Cetuximab plus XELOX show efficacy against brain metastasis from colorectal cancer: a case report
by: Ahmad KH Ibrahimi, et al.
Published: (2023-06-01)